A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Phase 3

Active, not recruiting

• Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension Due to Lung Diseases
• Interventions: Combination Product: L606 inhalation suspension

• Registration Number: NCT04691154
• Lead Sponsor: Liquidia Technologies, Inc.

Brief Summary

This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population; also evaluate the steady-state pharmacokinetics (PK) of L606 as compared to Tyvaso, effects on exercise ability, quality of life, and treatment satisfaction with L606.

Detailed Description

This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of repeated doses of L606 in patients with PAH or PH-ILD. The current Phase 3 study will help determine the short-term and long-term safety and tolerability of L606 in this patient population. The study will also evaluate the steady-state pharmacokinetics (PK) of L606 as compared to Tyvaso, effects on exercise ability (6-minute walk distance \[6MWD\] and Borg Dyspnea Score), quality of life (QoL), and treatment satisfaction with L606.

Subjects who meet all the inclusion criteria and none of the exclusion criteria will be enrolled to one of the 2 cohorts:

Cohort A: Subjects with PAH or PH-ILD receiving prior stable doses of Tyvaso (4 times daily) and willing to switch to L606 (twice daily).

Cohort B: Subjects with PAH (not initially on prostacyclin therapy) who are likely to receive clinical benefit from inhaled treprostinil based on the opinion of the investigator.

Cohort A subjects will sequentially participate in the MSP for 2 weeks and the OEP for 46 weeks. A subset of up to 15 subjects from Cohort A will also participate in a PK substudy. Cohort B subjects will sequentially participate in the MSP for 12 weeks and the OEP for 36 weeks.

Study Timeline

• Study First Submitted: 2020-12-21
• Study First Submitted QC: 2020-12-27
• Study First Posted: 2020-12-31
• Study Start: 2021-08-01
• Primary Completion: 2024-06-30
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-08
• Last Update Posted: 2024-10-09
• Study Completion: 2025-07-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

1. Able to understand and complete study requirements and provide written informed consent.

2. Males and females ≥18 and ≤80 years of age at the time of informed consent. All sexually active male subjects and female subjects of childbearing potential must use an acceptable, highly effective method of contraception.

3. Diagnosed with

   1. PAH belonging to at least 1 of the following subgroups of Group 1 pulmonary hypertension (PH) per European Society of Cardiology/European Respiratory Society Guidelines for the diagnosis and treatment of PH at least 1 year prior to screening. or
   2. PH-ILD Group 3 European Society of Cardiology/European Respiratory Society Guidelines for the diagnosis and treatment of PH. Subjects with Group 3 PH that is not related to underlying ILD are not eligible.

4. Subjects with PAH: Documentation of having PAH as confirmed by RHC within 12 months prior to screening and meeting the following criteria:

   i. Mean PAP >20 mmHg. ii. Pulmonary arterial wedge pressure ≤15 mmHg. iii. Pulmonary vascular resistance >3 Wood units. Subjects with PH-ILD: Confirmation of the underlying ILD must be based on HRCT imaging conducted within the past 12 months prior to randomization with demonstration of diffuse parenchymal lung disease and documented by the Investigator or radiology report. Subjects may have any form of ILD or CPFE.

5. NYHA functional class II, III, or IV at the screening visit.

6. Can complete a screening 6MWD of ≥150 meters

7. For subjects with PAH: >65% of predicted and FEV1/FVC ratio >65% at screening. For subjects with PH-ILD: >40% of predicted and FEV1/FVC ratio >70% at screening.

Key

Read More

Exclusion Criteria

1. LVEF of ≤45% on a historical echocardiogram within 6 months of screening.
2. History of sleep apnea, or left-sided heart disease (including but not limited to aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, or coronary artery disease) per investigator's discretion.
3. Experienced an acute exacerbation of disease or hospitalization for any reason within 30 days of signing the ICF or prior to baseline.
4. Systolic blood pressure <90 mmHg or ≥160 mmHg at baseline.
5. Screening electrocardiogram (ECG) with QTcF >525 ms.
6. Musculoskeletal disorder (eg, arthritis affecting the lower limbs, recent hip or knee joint replacement) or any disease that would likely be the primary limit to ambulation or subject is connected to a machine that is not portable enough to allow for a 6MWT.
7. Alanine aminotransferase or aspartate aminotransferase levels >3 × upper limit of normal reference range, clinically significant liver disease/dysfunction, or known Child-Pugh Class C hepatic disease.
8. Estimated glomerular filtration rate <30 mL/min/1.73 m2 or requires dialysis.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
L606	L606 inhalation suspension	-

Primary Outcome Measures

Name	Time	Method
Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs (long-term)	48 weeks	To evaluate the safety and tolerability of twice daily L606 dosing for up to 48 Weeks in patients with PAH or PH-ILD who choose to continue twice daily dosing with L606 beyond 2 weeks of the MSP for Cohort A or patients with PAH (not initially on prostacyclin therapy) who choose to continue twice daily dosing with L606 beyond 12 weeks of the MSP for Cohort B.
Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs	12 weeks	Proportion of patients with PAH (not initially on prostacyclin therapy) who would develop treatment-emergent AEs/SAEs during 12 weeks with titration on twice daily L606.

Secondary Outcome Measures

Name	Time	Method
Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs	12 months	Proportion of patients with PAH on a stable Tyvaso dose (4 times/day) who continue twice daily L606 dosing beyond 2 weeks, who would develop treatment-emergent AEs/SAEs for up to 12 months.
Pharmacokinetics assessed by steady-state PK parameters of treprostinil from Tyvaso and L606	2 weeks	Ratio (L606 at Week 2/Tyvaso at Day 1) of geometric means of average steady-state plasma concentrations of treprostinil (calculated over the dosing interval as Cavg) in patients with PAH or PH-ILD, assuming compliance with dosing requirements up to steady state.

Trial Locations

Locations (5)

Arizona Pulmonary Specialists; 🇺🇸 Phoenix, Arizona, United States

VA Greater Los Angeles Healthcare; 🇺🇸 Los Angeles, California, United States

Mayo Clinic Jacksonville; 🇺🇸 Jacksonville, Florida, United States

Brigham and Womens Hospital; 🇺🇸 Boston, Massachusetts, United States

UPMC Montefiore; 🇺🇸 Pittsburgh, Pennsylvania, United States